A globally popular, over-the-counter dietary supplement frequently taken by millions of older adults for joint pain and overall joint health has been linked to a potentially concerning outcome in individuals experiencing early cognitive problems.
Researchers at the University of Florida have found that the use of glucosamine is associated with a significantly greater likelihood that mild cognitive impairment will progress to full-blown dementia. Mild cognitive impairment, commonly referred to as MCI, describes measurable problems with memory, language, or other thinking skills that are greater than what would typically be expected with normal aging, yet do not necessarily interfere substantially with a person’s ability to manage everyday life and independent living.
The striking findings are the result of a large-scale retrospective analysis of patient health records, which was further supported by rigorous laboratory experiments involving human brain tissue and sophisticated mouse models of Alzheimer’s disease. While the researchers emphasize that the results remain preliminary and must ultimately be tested and validated through a dedicated human clinical trial, they point out that the data adds to a growing body of scientific evidence suggesting that disrupted metabolic processes may play a far more critical role in neurodegeneration than previously understood.
The comprehensive study was published in the prestigious scientific journal Nature Metabolism.
A Popular Supplement Comes Under Scrutiny
"In the United States, there are about 7 million people living with Alzheimer’s and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at the University of Florida’s McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."
Glucosamine is widely sold without a prescription in pharmacies, grocery stores, and online marketplaces around the world. It is especially popular among older adults who turn to the compound for relief from joint discomfort, stiffness, and long-term joint health maintenance. Because of how commonly the supplement is consumed, the research team wanted to investigate whether its regular use might influence Alzheimer’s disease and related dementias, collectively known in clinical research as ADRD.
To explore this potential connection, the researchers teamed up with Yi Guo, Ph.D., and Jiang Bian, Ph.D., utilizing advanced artificial intelligence and machine learning tools to analyze deidentified electronic health records collected by UF Health between 2012 and 2024.
The research team specifically focused their analytical lens on patients who had been formally diagnosed with either ADRD or mild cognitive impairment. Across both patient groups, approximately 8% of the individuals reported taking glucosamine. That subset included 1,896 patients living with ADRD and 2,750 patients dealing with mild cognitive impairment.
Glucosamine Linked to Dementia Progression
After carefully controlling and accounting for critical variables such as age, sex, and various demographic factors, the investigators discovered that glucosamine use was associated with a 25% higher likelihood that mild cognitive impairment would progress into clinical dementia over time.
Furthermore, among patients who had already been diagnosed with ADRD, the use of glucosamine was also associated with a 25% higher mortality risk, translating to a greater likelihood of death occurring during a defined observation period.
Interestingly, the researchers did not observe this same mortality association within the mild cognitive impairment group. This notable difference suggests that glucosamine may exert a stronger, more hazardous biological effect once dementia has already become established in the brain.
Despite these provocative correlations, the study authors emphasize that health record data alone cannot prove that glucosamine itself causes dementia to progress. While observational studies are powerful tools for revealing associations in large populations, other underlying lifestyle or health differences between people who choose to take supplements and those who do not may also contribute to the final results.
"The electronic health record data are very provocative," said Matt Gentry, Ph.D., chair of the UF Department of Biochemistry and Molecular Biology and a co-author of the study. "While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."
A Metabolic Pathway May Help Explain the Link
To move beyond mere observation, the researchers sought to uncover evidence of an underlying biological mechanism that could help explain the statistical link found in the patient data.
Their investigation points directly toward a specific metabolic pathway involving the attachment of sugar structures to cellular proteins. While this biochemical process, known as glycosylation, is a completely normal and vital part of healthy cell biology, the researchers found alarming signs that it becomes hyperactive and dysregulated in the brains of individuals with Alzheimer’s disease.
Dr. Sun noted that this abnormal activity within the metabolic pathway could eventually serve as a promising target for the development of entirely new therapeutic treatments.
"Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles," Sun said.
Amyloid-beta plaques and tau tangles are historically two of the most well-known pathological hallmarks of Alzheimer’s disease. Plaques consist of abnormal deposits of proteins that accumulate in the spaces between brain cells, while tangles are twisted fibers of the tau protein that develop inside neurons. While the vast majority of Alzheimer’s research has traditionally focused on clearing or preventing these classic abnormalities, scientists are increasingly turning their attention to additional cellular processes, such as metabolism, that significantly contribute to the onset and progression of the disease.
Mapping Thousands of Molecules in the Brain
To examine these complex metabolic changes in unprecedented detail, the researchers utilized a pioneering spatial technology developed directly within Sun’s laboratory.
"This technology allows us to examine thousands and thousands of molecules created when the body breaks down food or drugs and to uncover intricate pathways that otherwise would stay hidden," Sun explained.
The research team then focused their molecular analysis specifically on glucosamine. Glucosamine is a naturally occurring, sugar-related molecule that possesses the distinct ability to cross the blood-brain barrier, which is the highly protective physiological boundary that tightly regulates which substances are allowed to move from the circulating bloodstream into delicate brain tissue.
Once inside the central nervous system, glucosamine is capable of entering complex biochemical pathways that construct elaborate sugar structures and attach them to cellular proteins. Commercial glucosamine supplements consumed by the public are typically manufactured from raw materials, including the shells of shellfish or from corn.
According to the researchers, the physiological effects of glucosamine may depend heavily on the specific biological environment in which the molecule is operating. Consequently, a healthy, youthful brain and a brain actively damaged by Alzheimer’s disease may respond in drastically different ways to the exact same molecule. The data indicates that the Alzheimer’s-affected brain appears to be uniquely and dangerously vulnerable to this specific metabolic pathway.
Mouse Experiments Point to a Possible Mechanism
To test and explore this mechanism in a controlled biological system, the scientists conducted experiments utilizing genetically modified laboratory mice.
When the mice were administered glucosamine, the treatment significantly increased the attachment of sugar residues to proteins inside their cells. Concurrently, the glucosamine-treated mice developed markedly worse deficits in social memory and recognition memory compared to the control animals.
In a crucial follow-up test, when the researchers administered a chemical treatment designed to suppress the abnormal sugar-attachment process, the memory performance of the mice visibly improved.
This controlled experiment strongly suggested that excessive sugar tagging plays a direct, causal role in generating the memory problems observed in the animals, rather than simply occurring as an unrelated side effect alongside the cognitive decline.
Human Alzheimer’s Brain Tissue Shows the Same Pattern
Following the animal trials, the research team partnered with Stefan Prokop, M.D., to examine human brain tissue samples.
Specimens obtained from individuals who had passed away with Alzheimer’s disease—provided through the University of Florida Neuromedicine Brain and Tissue Bank—displayed significantly elevated levels of sugar attachment on proteins when compared directly against normal, healthy control tissue.
Combined with the preceding mouse experiments and the extensive electronic health record analysis, these findings strongly suggest that abnormal cellular metabolism is not merely a secondary consequence or downstream byproduct of Alzheimer’s disease. Instead, the data indicates that metabolic dysfunction actively contributes to the underlying disease process itself.
"Proteins are the cell’s molecular machines, and many of them need sugar tags added in just the right way to fold correctly, travel to the right place and do their jobs," Gentry said. "What we found in Alzheimer’s is that this sugar-tagging system appears to be overactive. The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it."
While the results raise serious and important questions regarding the casual use of glucosamine among individuals already grappling with cognitive impairment or dementia, the study authors caution that the findings do not yet establish definitive proof that patients should immediately stop taking the supplement. A rigorously controlled human clinical trial will be absolutely necessary to determine whether glucosamine directly accelerates the progression of Alzheimer’s disease and, if so, which specific patient populations are most vulnerable to its effects.